GNFT

Nitazoxanide

NASH-induced significant or severe fibrosis

Phase 2

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

Catalyst Events

  • TBA


Clinical Trial

  • NCT03656068: An Evaluation of the Safety and Efficacy of NTZ on Collagen Turnover in NASH Patients With Fibrosis


Time Line


Related Links


Prior Data Links

  • October 2019 Slide Deck

  • Foucart, C., Stankovic-Valentin, N., Parroche, P., Degallaix, N., Belanger, C., Birman, P., ... & Loomba, R. (2019, October). ELAFIBRANOR AND NITAZOXANIDE HAVE COMPLEMENTARY ACTIONS TO PROTECT AGAINST OXIDATIVE STRESS IN NASH. In HEPATOLOGY (Vol. 70, pp. 1312A-1313A). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.


HC updated 5/21/20

 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon